Biogen said that new data examining of its already approved spinal muscular atrophy treatment Spinraza (nusinersen) indicates ...

Biogen has paid Ionis a $75-million licensing fee for the drug, called nusinersen, Ionis Chief Executive Stanley T. Crooke said. The Cambridge, Mass., company’s shares rose 4.1%. Biogen plans to ...

Image source: Biogen, Inc. Biogen, Inc. (BIIB 0.86%) and partner Ionis Pharmaceuticals, Inc. (IONS 4.17%) reported this week that an interim look at a study evaluating the companies' nusinersen as ...

Biogen intends to market nusinersen under the brand name SPINRAZA TM. This name has been conditionally accepted by the FDA and the CHMP and will be confirmed upon approval.

New data from Biogen shows improved motor function in SMA patients using a higher dose of nusinersen, highlighting early treatment benefits. Biogen announced new data from the DEVOTE Part C and ...

Biogen Inc. announced that the FDA has accepted and the EMA has validated its supplemental New Drug Application for a higher dose regimen of nusinersen, intended for treating spinal muscular ...

Biogen shared Phase I trial results, highlighting the potential benefits of the SMA treatment while promoting its once-yearly ...

Biogen’s SPINRAZA® Data Show Earlier Treatment Initiation May Lead to Improved Motor Function Across a Broad Population of People Living with SMA. Biogen’s SPINRAZA® (nusinersen) ...

Biogen has paid Ionis a $75 million license fee after exercising its option to develop and commercialize nusinersen globally. Biogen is now responsible for all nusinersen development, regulatory ...

SPINRAZA becomes the first therapy recommended in the United Kingdom for 5q spinal muscular atrophy to treat all age groups, including patients who are pre-symptomatic More than 7,500 individuals ...

SPINRAZA is the standard of care for treating infants, children and adults with spinal muscular atrophy, a rare, genetic neuromuscular disease SPINRAZA was approved under the China National ...

Biogen Inc. BIIB and Ionis Pharmaceuticals IONS revealed that nusinersen, their investigational treatment for spinal muscular atrophy (SMA), met the primary endpoint at interim analysis of the ...